NEWEarnings
Atai Life Sciences (ATAI) Price Target Raised to $17 on MDD Plans
Published on 7/7/2026
AI Summary
Summarized by AI from the source belowCanaccord Genuity has increased its price target for Atai Life Sciences (ATAI) to $17, citing the company's plans related to Major Depressive Disorder (MDD). This adjustment reflects a positive outlook on Atai's potential developments in treating MDD. The forecast implies a significant anticipated market value and suggests investor confidence in the company's strategies. The upward revision could attract more investors, affecting the stock’s performance in the market.
Get the free market brief
Top stories and analysis, summarized. No spam, unsubscribe anytime.
